Clinical trialPhase 2Completed
Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Pancreatectomy ("RESQU-BLOCK" Trial)
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 28 February 2019
- Expected end
- 31 July 2025
- Enrollment
- 136 participants
- Sites
- 1
- Primary outcomes
- Number of Participants Discharged Opioid-Free
- Sponsor
- Other
- Results posted
- 2023-02-13
- Last update
- 23 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies how an additional anesthetic nerve block, called a quadratus lumborum block, works to reduce the need for opioids in patients after pancreatic surgery. Giving an additional regional anesthetic after surgery may hasten the weaning process, reduce the need for opioid medications upon discharge, and reduce the risk of opioid dependence.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVE: I. To use a phase II randomized controlled trial to compare the intervention of a second regional anesthetic block (quadratus lumborum \[QL\] block) versus usual care (single intraoperative QL block) to increase the proportion of opioid-free pancreatic cancer survivors at discharge after potentially curative surgery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery. ARM 2: Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care. After completion of study treatment, patients are followed up at 1 month, 3 months, 6 months, and 1 year after surgery.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants Discharged Opioid-Free [90 days from surgery]. Count Of Participants, Participants. Arm 1, Control Arm (Usual Care) (n=52): 19; Arm 2, Experimental Arm (2nd QL-Block) (n=53): 27. Analysis, Arm 1, Control Arm (Usual Care) vs Arm 2, Experimental Arm (2nd QL-Block): p=0.17; Chi-squared; other.